Building on these research findings, Eli Lilly developed a dual agonist targeting GLP-1R/GIPR, called tirzepatide, which was approved by the FDA in 2022 and showed promising therapeutic effects for T2D and obesity
doi:10.1186/s41256-025-00403-3 2
Switching from tirzepatide to semaglutide or vice versa is unlikely to resolve dry mouth if the mechanism is direct GLP-1 receptor activation in salivary glands
Graham DL, Durai HH, Trammell TS, Noble BL, Mortlock DP, Galli A, et al
showed that IL-1 significantly elevated BDNF, neurotrophin 3, neuropilin 2, and NGF expression in annulus cells
Preparing the Skin and Administering the Injection Wash hands thoroughly, use a new sterile needle for each injection, clean the skin with an alcohol swab, allow it to dry, then insert the needle at 90 degrees (or 45 degrees if slim) and inject slowly